San Diego—When added to the standard combination of lenalidomide and dexamethasone in previously untreated multiple myeloma (MM) patients ineligible for transplant, daratumumab significantly extends progression-free survival (PFS), according to newly presented phase 3 trial data.
"On the basis of these results, we believe that daratumumab should be considered the new standard of care for this patient group,” reported investigator Thierry Facon, MD, a professor of hematology at the